Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
PVLA compared with ARQT: revenue, margins and what each company keeps, and the suppliers and customers both name
PVLA
Palvella Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
ARQT
Arcutis Biotherapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
PVLA
Palvella Therapeutics, Inc.
vs
ARQT
Arcutis Biotherapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
PVLA
Palvella Therapeutics, Inc.
Change
151.57
▼
−0.89%
Mkt cap
—
Revenue
—
Revenue
—
ARQT
Arcutis Biotherapeutics, Inc.
Change
32.10
▲
+0.31%
Regular session
Nov 4 '26
Mkt cap
$3.9B
Revenue
$130M
Q2 FY26
Revenue
$376M
FY25
vs
Compare
Regular session
Nov 4 '26
PVLA
Palvella Therapeutics, Inc.
vs
ARQT
Arcutis Biotherapeutics, Inc.
151.57
▼
−0.89%
Price
32.10
▲
+0.31%
—
Mkt cap
$3.9B
—
Revenue
$130M
Q2 FY26
—
Revenue
$376M
FY25
Change
Change
PVLA
151.57
▼
−0.89%
vs
ARQT
32.10
▲
+0.31%
Regular session
Nov 4 '26
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
PVLA: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only PVLA
0
None
Shared
0
No disclosed counterparties: PVLA.
Only ARQT
5
AZN
AstraZeneca AB
supplier
—
Jiangsu Hengrui Medicine
unlisted
supplier
—
Hangzhou Zhongmei Huadong Pharmaceutical
unlisted
customer
—
Kowa Pharmaceuticals America
unlisted
customer
1 more · ARQT chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
PVLA, solid
ARQT, dashed